Portrait der Gilead Sciences Aktie
Das Unternehmen Gilead Sciences aus USA ist in den Bereichen Chemie & Pharma, Biotechnologie & Pharmazeutika, Biotechnologie, Pharma tätig.
Gilead Sciences ist in mehr als 83 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter iShares Nasdaq US Biotechnology UCITS ETF gewichtet Gilead Sciences mit 7,06% im ETF.
Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Gilead Sciences Anleihen auf einen Blick.
Entdecke die 6 ETFs in denen Gilead Sciences am höchsten gewichtet ist Insgesamt in 83 ETFs enthalten
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Gilead Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
288 News & Informationen zur Gilead Sciences Aktie
Covid-19 Pill Race Heats Up as Japanese Firm Vies With Pfizer, Merck
Japan’s Shionogi has started human trials for a once-a-day drug designed to neutralize the coronavirus in less than a week as Pfizer and Merck carry out later-stage tests.
Enochian BioSciences : Names The Hon. Dr. Mark Dybul as Chief Executive Officer (Form 8-K)
Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Honorable Mark Dybul, M.D. has been named as Chief… | July 23, 2021
MediciNova : BETWEEN THE IRVINE COMPANY LLC AND (Form 8-K)
BETWEEN
THE IRVINE COMPANY LLC
AND
MEDICINOVA, INC.
LEASE
… | July 23, 2021
BioNTech : Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S (Form 6-K)
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
… | July 23, 2021
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed at $68.41 in the latest trading session, marking a -1.08% move from the prior day.
How M&A Can Affect a Company
M&A can have a profound effect on a company’s growth prospects and outlook, but with a significant degree of risk.
Gilead Sciences : Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis
Foster City, Calif., July 21, 2021 –Gilead Sciences welcomes the positive findings of the AMBITION clinical trial that were presented today at the 11th International AIDS Society … | July 21, 2021
Ligand Pharmaceuticals Incorporated : Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Ligand expects to receive $7 million in milestone payments
Rylaze for the treatment of ALL or LBL utilizes Ligand’s Pelican Expression Technology™ Platform
… | July 21, 2021
Esker Therapeutics : Appoints New Team Members and Board Director
Esker Therapeutics, a Foresite Labs-incubated precision medicine company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointment of…
ICMR is making ‘questionable decisions’ on Covid in India
Scientists and medical researchers seek access to data with the Council
ICMR, public face of India's Covid response, comes under fire for decisions
Read more about ICMR, public face of India's Covid response, comes under fire for decisions on Business Standard. State-funded research group is accused of making questionable decisions on medicines and lack of transparency in its work
ADRs End Lower; Toyota, BioNTech Among Companies Actively Trading
By Kimberly Chin International stocks trading in New York closed lower on Monday. The S&P/BNY Mellon index of American depositary receipts fell 1.9% to 162.40. The European index…
2 Top Pharma Stocks to Buy Right Now
The market may be underappreciating the long-term prospects of Johnson & Johnson and Merck.
New Phase 3 Data Support The Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company's investigational,
Four-Year Biktarvy® Data Presented At IAS 2021 Demonstrate High Efficacy And Durable Viral Suppression In Treatment-Naïve Adults
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a pooled analysis of a 48-week open-label extension of two Phase 3 studies (Study 1489 and Study 1490)
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the latest trading session, Gilead Sciences (GILD) closed at $68.30, marking a +0.54% move from the previous day.
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next …
Global $140 Bn Over the Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025
/PRNewswire/ — The “Global Over the Counter (OTC) Drugs Market, By Product (Cough, Cold, and Flu, Analgesics, Dermatology Products, Vitamins, Mineral, and…
Global $140 Bn Over The Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025
DUBLIN, July 15, 2021 /PRNewswire/ — The “Global Over the Counter (OTC) Drugs Market, By Product (Cough, Cold, and Flu, Analgesics, Dermatology Products,
The TCR-based therapies market is projected to be worth around USD 4.4 billion, by 2030, claims Roots Analysis
Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority of TCR-based therapies, presenting lucrative opportunities…
Mein Einkommen Juni 2021: €528,05 – Jung in Rente
Mein stetig wachsendes Depot beschert mir ein regelmäßiges passives Einkommen. Dies ist mein monatlicher Einkommensbericht für Juni 2021.
Investing $72,036 Into These 3 Stocks Can Generate $300 in Monthly Income for Your Portfolio
And there's a good chance you could be earning even more than that.
Iterion Therapeutics Hires Jean Chang as Chief Operating Officer
HOUSTON, July 14, 2021 /PRNewswire/ — Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer …
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) — BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the…
Parnassus Endeavor Fund Buys 5 Stocks in 2nd Quarter
GuruFocus Article or News written by Margaret Moran and the topic is about: Socially responsible fund focuses more on health care with several new buys
Gilead Sciences Stock – Perfect Setup For Long Call Option (NASDAQ:GILD)
Given Gilead's current valuation, the large variance in possible scenarios, and the relatively low implied volatility, it is a perfect setup for a long call option play.
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief…
2 Biotech Stocks That are Dirt Cheap Right Now By StockNews
2 Biotech Stocks That are Dirt Cheap Right Now
2 Biotech Stocks That are Dirt Cheap Right Now
The biotech industry has received much attention lately for its contribution to the world’s fight against COVID-19. Furthermore, with the help of new…
Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer
MENLO PARK, Calif., July 12, 2021 — Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and… | July 12, 2021
Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics As Chief Human Resources And Communications Officer
MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated CORT, a commercial-stage company engaged in the discovery and
Enochian BioSciences : Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND request for a… | July 12, 2021
VectivBio Nominates Paul R. Carter And Murray W. Stewart For Election To Its Board Of Directors
– Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio – – Nominees will stand for election at an
Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary
/PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd., a clinical-stage, fast-growing biopharmaceutical company focusing on discovering and developing…
We got an exclusive look inside Moderna's labs, where the biotech upstart is planning what comes after its blockbuster coronavirus vaccine
The $90 billion biotech is making a fortune from its COVID-19 vaccine. But its rich valuation has also led to a fierce debate about Moderna's future.
Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?
The battle for market share could come down to which drug has the lesser side effects.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $68.22, moving +0.78% from the previous trading session.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $68.22, moving +0.78% from the previous trading session.
Top Stock Reports for JPMorgan, Intel & McDonald's
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Intel (INTC), and McDonald's (MCD).